

SECRETARY OF
05 SEP -9

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant name Loeffler Tuggey Pauerstein Rosenthal LLP d/b/a The Loeffler Group			
2. Address <input type="checkbox"/> Check if different than previously reported 1801 K Street, NW, Suite 340			
3. Principal place of business (if different from line 2)			
City	Washington	State/Zip (or Country)	DC 20006
4. Contact Name Wallace Henderson	Telephone 202-775-4435	E-mail (optional)	5. Senate ID 64634-
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research and Manufacturers of America (PhRMA)			6. House ID 355480

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report => Termination Date _____ 11. No Lobby Ac

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> => <u>\$80,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> => \$ _____ Expenses (nearest \$2</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of opti</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) c Internal Revenue Code</p>
--	--

Signature _____ Date _____

0000461246



Printed Name and Title _____

Form LD-2 (Rev 06/98)

P:

Registrant Name Loeffler Tuggey Pauerstein Rosenthal LLP Client Name Pharmaceutical Res. & Man. of Ar

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying activity on behalf of the client during the reporting period. **Using a separate page for eac** provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Pharmaceutical issues, SCR 18

Pharmaceutical market access, S 109, HR 328

Pharmaceutical importation, S 184

17. House(s) of Congress and Federal agencies contacted
House of Representatives, Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Tom Loeffler	
Wallace Henderson	
Julie Domenick	
Cynthia Farrell	
Kristen P. Gullott	

19. Interest of each foreign entity in the specific issues listed on the line 16 above

Check if None

Signature _____ Date _____

Printed Name and Title _____

0000461247



Registrant Name Loeffler Tuggey Pauerstein Rosenthal LLP Client Name Pharmaceutical Res. & Man. of Ar

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying activity on behalf of the client during the reporting period. **Using a separate page for eac** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues
Pharmaceutical research and development

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
NONE	
.....
.....
.....
.....
.....
.....
.....
.....

19. Interest of each foreign entity in the specific issues listed on the line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

0000461248

Registrant Name Loeffler Tuggey Pauerstein Rosenthal LLP Client Name Pharmaceutical Res. & Man. of Ar

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying activity on behalf of the client during the reporting period. **Using a separate page for eac** provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues
Patent reform, HR 2795

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Tom Loeffler	
Wallace Henderson	
Julie Domenick	
Cynthia Farrell	
Kristen P. Gullott	

19. Interest of each foreign entity in the specific issues listed on the line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

0000461249



Registrant Name Loeffler Tuggey Pauerstein Rosenthal LLP Client Name Pharmaceutical Res. & Man. of Ar

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying activity on behalf of the client during the reporting period. **Using a separate page for eac** provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues
Pharmaceuticals and health care

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
NONE	
.....
.....
.....
.....
.....
.....
.....
.....

19. Interest of each foreign entity in the specific issues listed on the line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

0000461250



Registrant Name Loeffler Tuggey Pauerstein Rosenthal LLP Client Name Pharmaceutical Res. & Man. of Ar

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying activity on behalf of the client during the reporting period. **Using a separate page for eac** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MAN (one per page)

16. Specific lobbying issues
Pharmaceutical manufacturing issues

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
NONE	
.....	
.....	
.....	
.....	
.....	
.....	
.....	
.....	

19. Interest of each foreign entity in the specific issues listed on the line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

0000461251



Registrant Name Loeffler Tuggey Pauerstein Rosenthal LLP Client Name Pharmaceutical Res. & Man. of Ar

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying activity on behalf of the client during the reporting period. **Using a separate page for eac** provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues
Pharmaceutical importation, S 184

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives, Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Tom Loeffler	
Wallace Henderson	
Julie Domenick	
Cynthia Farrell	
Kristen P. Gullott	

19. Interest of each foreign entity in the specific issues listed on the line 16 above Check if None

Signature  Date 8/30/05

3000461252

Form LD-2 (Rev 06/98)